Breaking News

You are here » Indian-Commodity  :  Commodities  :  Turmeric  :  Turmeric futures exhibit mixed trend on NCDEX

20-Nov2017

Turmeric futures exhibit mixed trend on NCDEX

Turmeric futures showed mixed trend on NCDEX as November contract edged lower as good supplies from the government auctions and arrivals of medium quality supplies pressurized prices. While, December contract edged up amid strong demand in the spot market.

The contract for November delivery was trading Rs 7100.00, down by 0.14% or Rs 10.00 from its previous closing of Rs 7110.00. The open interest of the contract stood at 40 lots.

The contract for December delivery was trading at Rs 7116 .00, up by 1.19% or Rs 84.00 from its previous closing of Rs 7032.00. The open interest of the contract stood at 6740 lots on NCDEX.


Related News

View all news

Turmeric futures trade lower on improved crop prospects

Turmeric futures traded lower on NCDEX, due to trimming of bets by market players on the back of improved crop prospects in Maharashtra. Further, expectation of fresh arrivals at the spot market amid sufficient......

Turmeric futures trade mixed on NCDEX

Turmeric futures traded mixed on NCDEX, as contract for April traded up on the back of concerns that drought conditions and cold weather will affect the crop production, while contract for May traded down......

Turmeric futures trade lower on NCDEX

Turmeric futures traded lower on NCDEX, on the back of improved crop prospects in Maharashtra. Further, expectation of higher production this season due to higher acreage in Telangana also fuelled the......

Top News

View all news

Tata Motors signs LTS agreement with its employees

Tata Motors has signed a long-term wage settlement (LTS) agreement with its employees. Under the agreement, workmen will get a wage rise of Rs 9,000 per month along with other incentives based on performance.......

Canara Bank invites bids from merchant bankers to manage its $350-500 million MTN issue: Report

Canara Bank has reportedly invited bids from merchant bankers to manage its $350-500 million issue of senior unsecured/tier-II capital bonds under its medium-term note (MTN) programme. The issue size may......

Alembic Pharma gets USFDA's nod for Acetazolamide Extended-Release Capsules

Alembic Pharmaceuticals (Alembic) has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acetazolamide Extended-Release Capsules, 500......